[go: up one dir, main page]

EE200200393A - Glüburiidi ravimkoostis - Google Patents

Glüburiidi ravimkoostis

Info

Publication number
EE200200393A
EE200200393A EEP200200393A EEP200200393A EE200200393A EE 200200393 A EE200200393 A EE 200200393A EE P200200393 A EEP200200393 A EE P200200393A EE P200200393 A EEP200200393 A EE P200200393A EE 200200393 A EE200200393 A EE 200200393A
Authority
EE
Estonia
Prior art keywords
glyburide
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
EEP200200393A
Other languages
English (en)
Inventor
Cave Gillian
J. Nicholson Sarah
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of EE200200393A publication Critical patent/EE200200393A/et
Publication of EE05020B1 publication Critical patent/EE05020B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
    • C07C311/57—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/59—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of rings other than six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cephalosporin Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
EEP200200393A 2000-01-14 2001-01-04 Glburiidi ravimkoostis EE05020B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48370300A 2000-01-14 2000-01-14
PCT/US2001/000234 WO2001051463A1 (en) 2000-01-14 2001-01-04 Glyburide composition

Publications (2)

Publication Number Publication Date
EE200200393A true EE200200393A (et) 2003-10-15
EE05020B1 EE05020B1 (et) 2008-06-16

Family

ID=23921174

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200393A EE05020B1 (et) 2000-01-14 2001-01-04 Glburiidi ravimkoostis

Country Status (37)

Country Link
US (2) US20010036479A1 (et)
EP (1) EP1250321B1 (et)
JP (1) JP4787446B2 (et)
KR (1) KR100739906B1 (et)
CN (1) CN1210258C (et)
AR (1) AR031547A1 (et)
AT (1) ATE330937T1 (et)
AU (1) AU771705B2 (et)
BG (1) BG65782B1 (et)
BR (1) BR0107564A (et)
CA (1) CA2397294C (et)
CY (1) CY1106328T1 (et)
CZ (1) CZ20022429A3 (et)
DE (1) DE60120916T2 (et)
DK (1) DK1250321T3 (et)
EE (1) EE05020B1 (et)
ES (1) ES2264967T3 (et)
GE (1) GEP20043299B (et)
HU (1) HU228825B1 (et)
IL (2) IL150383A0 (et)
LT (1) LT5024B (et)
LV (1) LV12914B (et)
MX (1) MXPA02006835A (et)
MY (1) MY128577A (et)
NO (1) NO328152B1 (et)
NZ (1) NZ519920A (et)
PT (1) PT1250321E (et)
RO (1) RO121381B1 (et)
RU (1) RU2244707C2 (et)
SK (1) SK286925B6 (et)
TN (1) TNSN01005A1 (et)
TR (1) TR200201798T2 (et)
TW (1) TWI287989B (et)
UA (1) UA73968C2 (et)
UY (1) UY26529A1 (et)
WO (1) WO2001051463A1 (et)
ZA (1) ZA200205528B (et)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767249B2 (en) * 2001-06-07 2010-08-03 Hewlett-Packard Development Company, L.P. Preparation of nanoparticles
US20050271737A1 (en) * 2001-06-07 2005-12-08 Chinea Vanessa I Application of a bioactive agent to a substrate
IL164154A0 (en) * 2002-03-21 2005-12-18 Teva Pharma Fine particle size pioglitazone
KR100897890B1 (ko) 2002-06-17 2009-05-18 인벤티아 헬스케어 피브이티. 엘티디. 티아졸리딘디온 및 바이구아나이드를 함유하는 다층 정제및 그의 제조 방법
CN1874774B (zh) 2003-10-31 2011-04-13 武田药品工业株式会社 包含胰岛素致敏剂、胰岛素促分泌素和聚氧乙烯脱水山梨醇脂肪酸酯的固体制剂
AU2004318976B2 (en) * 2004-04-29 2009-04-09 Lotus Pharmaceutical Co., Ltd. Oral modified-release lozenges and their preparation method
RU2359677C2 (ru) * 2004-04-29 2009-06-27 Лотус Фармасьютикал Ко., Лтд Оральные таблетки с модифицированным высвобождением и способ их получения
CN100455279C (zh) * 2004-04-29 2009-01-28 美时化学制药股份有限公司 口服延迟释放锭剂组成物及其制法
CN100341495C (zh) * 2004-12-29 2007-10-10 三九医药股份有限公司 格列本脲固体分散体、口服组合物及其制备方法
WO2006109175A2 (en) * 2005-04-11 2006-10-19 Aurobindo Pharma Limited Solid dosage form of an antidiabetic drug
US8529537B2 (en) * 2005-08-05 2013-09-10 Kimberly-Clark Worldwide, Inc. Absorbent article with enclosures
JP5113752B2 (ja) 2005-08-22 2013-01-09 メリオール・ファーマスーティカルズ・ワン・インコーポレイテッド Ｌｙｎキナーゼの活性を調節し、関連する疾患を治療するための方法および製剤
CN101287467B (zh) * 2005-08-22 2011-01-19 梅里奥尔医药I公司 用于调节Lyn激酶活性和治疗相关病症的方法和制剂
JP2009537478A (ja) * 2006-05-13 2009-10-29 ノヴォ ノルディスク アクティーゼルスカブ レパグリニドとメトホルミンを含む錠剤配合物
WO2008026668A1 (en) * 2006-08-31 2008-03-06 Daiichi Sankyo Company, Limited Medicinal composition containing insulin resistance improving agent
EP1967182A1 (en) * 2007-03-07 2008-09-10 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a salt of rosigliatazone
US8552184B2 (en) 2008-07-03 2013-10-08 Melior Pharmaceuticals I, Inc. Compounds and methods for treating disorders related to glucose metabolism
WO2010048287A2 (en) 2008-10-22 2010-04-29 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Radioprotective agents
SG173032A1 (en) 2009-02-13 2011-08-29 Boehringer Ingelheim Int Pharmaceutical composition comprising glucopyranosyl diphenylmethane derivatives, pharmaceutical dosage form thereof, process for their preparation and uses thereof for improved glycemic control in a patient
WO2011150300A1 (en) 2010-05-28 2011-12-01 Melior Pharmaceuticals I, Inc. Prevention of pancreatic beta cell degeneration
EP2520298A1 (en) 2011-05-03 2012-11-07 Assistance Publique, Hopitaux De Paris Pharmaceutical composition comprising sulfonylureas (glibenclamide) or meglitinides for use for treating hyperglycaemia or for promoting growth of a premature infant
CN102743354A (zh) * 2012-07-31 2012-10-24 南京正科制药有限公司 瑞格列奈片及其制备方法
CN103142521B (zh) * 2013-03-21 2014-06-25 西南药业股份有限公司 格列本脲片及其制备方法
CN104127423A (zh) * 2014-07-30 2014-11-05 沈阳药科大学 格列喹酮衍生物及其制备方法和应用
CN104127424A (zh) * 2014-07-30 2014-11-05 沈阳药科大学 格列本脲衍生物及其制备方法和应用
JP7182605B2 (ja) 2017-04-10 2022-12-02 メリオール・ファーマスーティカルズ・ワン・インコーポレイテッド ｌｙｎキナーゼ活性化因子及びＴＲＰＭ８アゴニストを含む組成物及び医薬の製造におけるそれらの使用
CN113143940A (zh) * 2020-12-30 2021-07-23 成都恒瑞制药有限公司 一种抗糖尿病药物组合物的制备方法
WO2022187567A2 (en) 2021-03-04 2022-09-09 Biogen Chesapeake Llc Low-sorbing glyburide formulation and methods
WO2023012610A1 (en) * 2021-08-03 2023-02-09 Avaca Pharma Private Limited Formulations, compositions and methods for the treatment of stroke

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) * 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
DE1185180B (de) 1963-10-19 1965-01-14 Hoechst Ag Verfahren zur Herstellung von Benzolsulfonylharnstoffen
US3454635A (en) 1965-07-27 1969-07-08 Hoechst Ag Benzenesulfonyl-ureas and process for their manufacture
CA889876A (en) 1970-09-10 1972-01-04 Frank W. Horner Limited Purification of glyburide
DE2348334C2 (de) * 1973-09-26 1982-11-11 Boehringer Mannheim Gmbh, 6800 Mannheim Neue Zubereitungsform des N-4-[2-(5-Chlor-2-methoxybenzamido)äthyl]- phenyl-sulfonyl-N'-cyclohexylharnstoffs
US4060634A (en) * 1973-09-26 1977-11-29 Boehringer Mannheim G.M.B.H. Rapidly resorbable glibenclamide
US4916163A (en) * 1985-06-04 1990-04-10 The Upjohn Company Spray-dried lactose formulation of micronized glyburide
DE3833439A1 (de) 1988-10-01 1991-09-12 Hoechst Ag Verfahren zur mikronisierung von glibenclamid
RU2026670C1 (ru) 1988-10-05 1995-01-20 Дзе Апджон Компани Способ получения тонкодисперсного твердого фармацевтического вещества
US5258185A (en) * 1989-08-23 1993-11-02 Bauer Kurt H Highly active, rapidly absorbable formulations of glibenclamide, processes for the production thereof and their use
ATE137962T1 (de) * 1991-12-05 1996-06-15 Alfatec Pharma Gmbh Pharmazeutisch applizierbares nanosol und verfahren zu seiner herstellung
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
DE4323636A1 (de) * 1993-07-15 1995-01-19 Hoechst Ag Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
IT1276130B1 (it) 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
DE19721467A1 (de) * 1997-05-22 1998-11-26 Basf Ag Verfahren zur Herstellung kleinteiliger Zubereitungen biologisch aktiver Stoffe
ID23372A (id) 1997-06-18 2000-04-20 Smithkline Beecham Plc Pengobatan diabetes dengan tiazolidindion dan metformin
GB9715306D0 (en) 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
WO1999021534A1 (en) * 1997-10-27 1999-05-06 Merck Patent Gmbh Solid state solutions and dispersions of poorly water soluble drugs
EP0974356B1 (en) 1998-07-15 2003-09-24 Merck Sante Tablets comprising a combination of metformin and glibenclamide
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents

Also Published As

Publication number Publication date
TNSN01005A1 (en) 2005-11-10
PT1250321E (pt) 2006-09-29
WO2001051463A1 (en) 2001-07-19
KR100739906B1 (ko) 2007-07-16
JP4787446B2 (ja) 2011-10-05
US20010036479A1 (en) 2001-11-01
RU2244707C2 (ru) 2005-01-20
UY26529A1 (es) 2001-08-27
TR200201798T2 (tr) 2002-11-21
ES2264967T3 (es) 2007-02-01
LT2002085A (en) 2003-01-27
CA2397294C (en) 2011-03-22
BR0107564A (pt) 2002-10-01
AU2474001A (en) 2001-07-24
HUP0203852A2 (hu) 2003-04-28
CZ20022429A3 (cs) 2003-06-18
SK9832002A3 (en) 2003-07-01
CN1210258C (zh) 2005-07-13
BG65782B1 (bg) 2009-11-30
NO20023367L (no) 2002-09-04
CA2397294A1 (en) 2001-07-19
JP2003519681A (ja) 2003-06-24
IL150383A (en) 2007-03-08
ZA200205528B (en) 2003-10-10
US20030185880A1 (en) 2003-10-02
AU771705B2 (en) 2004-04-01
KR20020073169A (ko) 2002-09-19
HUP0203852A3 (en) 2005-05-30
DE60120916D1 (de) 2006-08-03
EP1250321B1 (en) 2006-06-21
EE05020B1 (et) 2008-06-16
EP1250321A1 (en) 2002-10-23
DE60120916T2 (de) 2007-02-15
SK286925B6 (sk) 2009-07-06
UA73968C2 (en) 2005-10-17
ATE330937T1 (de) 2006-07-15
MXPA02006835A (es) 2003-01-28
NZ519920A (en) 2004-06-25
US6830760B2 (en) 2004-12-14
NO328152B1 (no) 2009-12-21
MY128577A (en) 2007-02-28
RU2002121626A (ru) 2004-01-10
AR031547A1 (es) 2003-09-24
CY1106328T1 (el) 2011-10-12
LV12914B (en) 2003-01-20
LT5024B (lt) 2003-06-25
IL150383A0 (en) 2002-12-01
PL356210A1 (en) 2004-06-14
RO121381B1 (ro) 2007-04-30
BG106870A (en) 2003-03-31
GEP20043299B (en) 2004-03-10
HU228825B1 (en) 2013-05-28
CN1395560A (zh) 2003-02-05
NO20023367D0 (no) 2002-07-12
TWI287989B (en) 2007-10-11
DK1250321T3 (da) 2006-07-31

Similar Documents

Publication Publication Date Title
EE200200393A (et) Glüburiidi ravimkoostis
DK1524266T3 (da) Farmaceutisk sammensætning
NO20025450L (no) Ny farmasöytisk sammensetning
AR028204A1 (es) Composiciones farmaceuticas electrohiladas
FI20105657L (fi) Farmaseuttisia koostumuksia
ITTO20010008A0 (it) Formulazione farmaceutica
ITMI20010748A0 (it) Composizioni farmaceutiche
FI991485L (fi) Uusi farmaseuttinen koostumus
NO20015175L (no) Farmasöytisk sammensetning
FI20011478L (fi) Farmaseuttinen koostumus
PT1253932E (pt) Composicoes farmaceuticas de toxina botulinica
AT7729U3 (de) Pharmazeutische zusammensetzungen enthaltend amlodipinmaleat
NO20026123L (no) Farmasöytiske sammensetninger
FI20022128A7 (fi) Farmaseuttinen koostumus
NO20031095D0 (no) Farmasöytiske sammensetninger
ITMI20011637A0 (it) Composizione farmaceutica contenente citalopram
PT1227817E (pt) Composicao farmaceutica aquosa contendo ciclesonida
FI4488U1 (fi) Farmaseuttinen koostumus
EE200300468A (et) Pravastatiini stabiilne farmatseutiline kompositsioon
NO20032957L (no) Farmasöytisk emulsjonspreparat
EE200200689A (et) Ravimkoostised
EP1413314A4 (en) MEDICAL COMPOSITIONS
DK200100203U4 (da) Farmaceutisk komposition indeholdende citalopram
FI5468U1 (fi) Farmaseuttinen koostumus
SE0000934D0 (sv) Method of preparing pharmaceutical compositions

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231